May 12, 2005 09:49 ET

Standard & Poor's Stock Reports Gives Nymox ''Bullish'' Rating

MAYWOOD, N.J.--(CCNMatthews - May 12, 2005) -

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) received favorable coverage in a new Standard & Poor's Stock Report. The new report on Nymox rates the stock as "bullish" on technical evaluation. The Stock Report was written by S&P analyst Craig C. Pratesi. The new three page report analyzes the company's business activities and stock performance.

This new positive report follows on considerable recent positive news from the Company. The Company recently announced that its AlzheimAlert™ urine test was advancing to an FDA Advisory Panel meeting. The Company also announced that it had signed marketing and distribution deals for this product in Italy with Alifax S.p.A. and in the Czech Republic with Klinlab Ltd. Nymox announced at the end of 2004 that it had received the European certification CE Mark for its AlzheimAlert™ urinary test kit device for the diagnosis of Alzheimer's Disease. Nymox's TobacAlert™ tobacco product exposure and second hand smoke test is carried nationally by CVS Stores in the U.S., which has over 5400 pharmacy stores throughout the country. Nymox holds U.S. and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The Company's new drug treatment for benign prostatic hyperplasia is currently at the stage of large pivotal testing. The Company's products have received numerous positive recommendations in the press.

More information about Nymox is available at http://www.nymox.com, email: info@nymox.com, or 1-800-936-9669.

This press release contains certain forward-looking statements as defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information